First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational New Drug (IND)
FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing
Chemically defined media optimized for growth and productivity of CHO cells in perfusion and batch and fed-batch bioprocesses
Avacta opens first two US Clinical Investigator sites for AVA6000 Phase 1 clinical study
Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center now open for patient enrolment to pre|CISION™ lead programme, AVA6000
Avacta announces first patient dosed in fifth cohort of AVA6000 Phase Ia Dose Escalation Study
Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000.
Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO
Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syn
Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals
Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeut
CrestOptics launches CICERO system to provide all-in-one solution for widefield and spinning disk confocal microscopy
CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced the launch of its new spinning disk confocal microscope system, CICERO.
Avacta appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer of its Therapeutics Division.
Bio-Rad Launches PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers
Enhanced usability to support PCR applications in basic and translational research, process development, and quality control
Gyros Protein Technologies introduces new PurePep EasyClean services to accelerate development and manufacturing of peptide-based drugs
Uppsala, Sweden - Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents, and a pioneer in automated nanoliter-scale immunoassays, announces the launch of three service offerings to support development and manufacturing of peptide-based drugs. The new services are based on the Company’s PurePep® EasyClean (PEC) orthogonal peptide purification technology.
Bio-Rad Introduces StarBright Blue and StarBright Yellow Dyes to Enhance Multiplex Flow Cytometry
StarBright Blue and StarBright Yellow Dyes Conjugated to Highly Validated Antibodies for Conventional and Full Spectrum Flow Cytometry in Immunology Research
H.E.L Group appoints Allen Wang as General Manager of H.E.L China
Appointment follows successful expansion of operations in China and transition to direct sales model
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems
MIP Discovery secures significant funding to support development of global rapid response diagnostics
Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale testing in low to middle-income countries.
Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics
Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by ca
Pangaea Data Named “Digital Solution of the Year” by the UK Government’s Department for International Trade (DIT)
Pangaea Data, (Pangaea), provider of a novel AI-driven product for characterizing patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, today announced that it has been named “Digital Solution of the Year” by the UK
Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field
Supporting Master’s student in Prof Helen Walden’s laboratory Project aims to determine USP30 structure to inform the design and discovery of novel inhibitors
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort
Pheno Therapeutics announces worldwide license from UCB to a novel program for neurodegenerative disease
Preclinical program with potential for disease modifying therapeutic
FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production
Chemically defined, BalanCD HEK293 Viral Feed enhances viral vector production for gene therapy applications and viral vector-based vaccines
Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that it has entered into a strategic, multi-phase collaboration wi